A gene-modified, autologous T-cell therapy expressing a chimeric antigen receptor targeting CD19. Upon binding CD19 on B-lineage cells, CAR-T cells activate independently of the native TCR, expand, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity to clear CD19+ leukemic blasts, causing B-cell aplasia.
Autologous gene‑modified T cells expressing a CD19‑targeted chimeric antigen receptor bind CD19 on B‑lineage cells, triggering CAR signaling independent of the native TCR. This activates and expands the T cells, induces cytokine release, and mediates perforin/granzyme‑dependent cytotoxic killing of CD19+ leukemic blasts, resulting in depletion of malignant and normal B cells (B‑cell aplasia).
CAR-T cells bind CD19 on target B cells, activate, and kill via perforin/granzyme-mediated cytolysis (and related apoptosis pathways).
Investigational apheresis-derived therapeutic immune cell product administered as a single IV infusion (dose-escalation 5.0×10^7 to 3.0×10^9 cells) for refractory/recurrent/metastatic digestive tract cancers; adoptive cellular immunotherapy intended to recognize a tumor-associated target protein and mediate T/NK-like cytotoxic killing of malignant cells.
Adoptive transfer of apheresis-derived immune effector cells that are expanded/activated ex vivo to recognize a tumor-associated target protein and kill malignant cells via T/NK cell–like cytotoxic mechanisms (e.g., perforin/granzyme-mediated lysis).
Adoptively transferred immune effector cells recognize the tumor-associated target and directly lyse antigen-positive cells via T/NK cytotoxicity (perforin/granzyme-mediated apoptosis).
A CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that binds CD20 on B cells and CD3 on T cells to activate cytotoxic T cells and eliminate CD20+ lymphoma cells.
A CD20xCD3 bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells, cross-linking and activating cytotoxic T cells to form immune synapses and lyse CD20-positive malignant B cells.
CD20xCD3 bispecific antibody crosslinks T cells to CD20+ cells, activating cytotoxic T cells to deliver perforin/granzymes and lyse/apoptose the target cells.
A glycoengineered type II anti‑CD20 monoclonal antibody that depletes B cells via ADCC and direct cell death; used as a lead‑in to debulk disease and reduce cytokine‑release risk.
Obinutuzumab is a glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via enhanced Fc gamma RIIIa–mediated ADCC and direct, caspase-independent apoptosis; it is often used as a lead-in to debulk disease and reduce cytokine-release risk.
Binds CD20 on B cells and induces killing via enhanced FcγRIIIa-mediated ADCC by NK cells/macrophages and by direct, caspase‑independent apoptosis (with minimal CDC).
Lentivirally modified T cells expressing a CAR against CD79b (BCR component); IV infusion with dose escalation; intended for MHC-independent elimination of CD79b+ B-cell malignancies.
Gene-modified T cells express a chimeric antigen receptor that recognizes CD79b on B-cell malignancies; CAR engagement activates T cells in an MHC-independent manner, inducing proliferation, cytokine release, and perforin/granzyme-mediated killing of CD79b-positive tumor cells.
CD79b-specific CAR T cells recognize CD79b on B cells and directly kill them via T‑cell activation and perforin/granzyme-mediated cytolysis (MHC‑independent).